About the Journal
Open Access
This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the Budapest Open Access Initiative (BOAI) definition of open access.
Scope
Cancer Research Communications is an open access peer-reviewed journal that encompasses the full spectrum of research on cancer. Launched in October 2021, the journal aims to accelerate the pace of discovery and stimulate innovation in cancer science and medicine by providing a venue for rapid open publication of hypotheses, methods, results, data resources, and new knowledge in all the varied disciplines of this quickly evolving field. Basic, translational, clinical, and population-level cancer research advances all fall within the scope of Cancer Research Communications. Articles report novel findings, provide support to previously published results, or present thought-provoking null results.
Frequently Asked Questions
Learn more about Cancer Research Communications on its FAQ page
Guidelines for Consideration
For publication in Cancer Research Communications, studies must represent tangible and valuable contributions to the cancer science and medicine community, either broadly or to a more specialized discipline. Studies must be based upon high-quality data derived from technically sound experimentation; be described in such a way that ensures reproducibility; be accessible to a broad audience; and be of value and utility to the field. Accordingly, studies must be scientifically transparent and written in a way that is interpretable to the broad cancer research community, with all materials, methods, and results fully and rigorously described. See "Research Articles" below for basic manuscript parameters and Information for Authors for more details on policies, processes, and submission.
Sections
Cancer Research Communications publishes content in nine sections that reflect its broad overall scope. Section names and descriptions follow:
- Molecular and Cellular Biology: Studies that investigate cancer-associated biochemical and molecular pathways and their influence on cell biology and carcinogenesis
- Tumor Biology: Studies that investigate the intercellular interactions and physiology governing tumor development and progression
- Immuno-oncology: Studies that investigate the immune system, its interactions with tumor cells, and opportunities to enhance the body's natural defenses against cancer
- Therapeutic Research and Development: Translational studies that investigate molecular targets, lead compounds, and experimental therapies in a preclinical setting
- Emerging Technologies and Data Science: Studies, methods, and large datasets that employ computational biology, high-throughput techniques, imaging, physical sciences, or engineering to investigate cancer biology
- Precision Medicine and Biomarkers: Clinical or translational studies aimed at optimally matching patients to treatments, including biomarkers and resistance mechanisms
- Clinical Research and Trials: Studies involving patients that investigate the efficacy of novel screening strategies, therapeutics, combinations, or regimens in the setting of clinical investigation
- Epidemiology and Prevention: Population-level studies that investigate the genetic and environmental risk factors of cancer and their application in disease prevention and interception
- Health Policy and Outcomes Research: Studies that investigate the cause and impact of differences in patient group outcomes, cancer survivorship, and the development of health policy from individual or population-level perspectives with a focus on health disparities and translational diversity
Each section is steered by a Senior Editor who is a leader in the field with support from a team of expert Associate Editors who oversee manuscript consideration. See Editors for details.
During the submission process, the corresponding author may choose the section to which they would like to direct their manuscript. Please note that our editors are empowered to change the section heading, thereby redirecting the paper, if they believe that it would be better suited for consideration within another section.
Research Article
Research Articles communicate original advances of value to the cancer research community as outlined in “Scope” and “Guidelines for Consideration” above. Parameters for a Research Article follow:
- 250-word unstructured abstract for a regular research article; 250-word structured abstract for a research article describing a clinical trial
- 50-word "Significance" statement, written for a broad audience, following the abstract
- No word limit, though we ask that your presentation be as concise as possible
- No reference limit, though we ask that you cite material that is as relevant and timely as possible
- Suggested display item (figure/table) limit of 8
Please note that our editors are empowered to request a reduction in manuscript length or display item count on a case-by-case basis if they believe that shortening the presentation would improve the study’s readability significantly.
Contact
Cancer Research Communications Editorial Office
American Association for Cancer Research | Publications Division
615 Chestnut Street | 17th Floor | Philadelphia, PA 19106-4404
Phone: (215) 440-9300 | Fax: (215) 440-9337 | E-mail: crc@aacr.org
